Overview Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC) Status: Terminated Trial end date: 2011-07-01 Target enrollment: Participant gender: Summary To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma Phase: Phase 2 Details Lead Sponsor: Seoul National University HospitalCollaborator: Clinical Research Center for Solid Tumor, KoreaTreatments: Docetaxel